
|Articles|June 12, 2020
Survival benefit in advanced or metastatic breast cancer with visceral metastases
Author(s)Lindsey Carr, Editor
Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
Advertisement
The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.
Learn more and read the full article from
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Nonhormonal therapies transform menopause care in 2025
2
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more
3
FDA clears FemVue Controlled for in-office tubal assessment
4
Objective blood loss measures reveal higher postpartum hemorrhage rates
5










